SeaCrest Wealth Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

SeaCrest Wealth Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,200	Closed	-$250K	–	572
2019 Q2	$250K	Sell	9,200 -850	-8%	-$26.7K	0.05%	417
2019 Q1	$349K	Buy	10,050 +9,050	+905%	+$261K	0.06%	324
2018 Q4	$20K	Sell	1,000 -5,450	-84%	-$112K	﹤0.01%	1247
2018 Q3	$172K	Buy	6,450 +1,400	+28%	+$45.7K	0.03%	559
2018 Q2	$191K	Buy	+5,050	New	+$193K	0.03%	506

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

SeaCrest Wealth Management's PTLA Position: Q3 2019 in Review

SeaCrest Wealth Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2019, closing a stake of 9,200 shares — an estimated $250K sold.

SeaCrest Wealth Management first reported a position in PTLA in Q2 2018 and held it in 5 quarters. The position peaked at $349K in Q1 2019. 212 funds tracked by Wall St. Rank hold PTLA as of Q3 2019.

SeaCrest Wealth Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 9,200 Portola Pharmaceuticals, Inc. shares in Q3 2019, an estimated $250K.
SeaCrest Wealth Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2018 and held it in 5 quarters.
SeaCrest Wealth Management's Portola Pharmaceuticals, Inc. position peaked at $349K in Q1 2019.
212 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2019.

Based on SeaCrest Wealth Management's 13F filing for Q3 2019, filed 15 Oct 2019.